Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of anti-PD-1 antibodies in combination with paclitaxel and platinum compounds in preparation of medicaments for treatment of esophageal cancer

A PD-1 and compound technology is applied in the field of use of anti-PD-1 antibodies combined with paclitaxel and platinum compounds in the preparation of drugs for the treatment of esophageal cancer, and can solve the problems of esophageal cancer that have not yet been seen with immune checkpoint inhibitors.

Inactive Publication Date: 2020-03-06
JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Immunotherapy for esophageal cancer has been reported. For example, immune checkpoint inhibitors Nivolumab, Pembrolizumab, and BGB-A317 are being clinically studied in combination with chemotherapy in the first-line treatment of advanced esophageal cancer. The combined chemotherapy drugs are fluorouracil and cisplatin, such as NCT03146153, NCT03189719 and CTR20170515, but there is no report on the treatment of esophageal cancer with immune checkpoint inhibitors combined with chemotherapy drugs paclitaxel and platinum compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anti-PD-1 antibodies in combination with paclitaxel and platinum compounds in preparation of medicaments for treatment of esophageal cancer
  • Use of anti-PD-1 antibodies in combination with paclitaxel and platinum compounds in preparation of medicaments for treatment of esophageal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Inclusion criteria:

[0109] Enrolled subjects were histologically or cytologically confirmed unresectable locally advanced / recurrent (cannot receive radical treatment such as radical chemoradiotherapy or radical radiotherapy) or distantly metastatic esophageal squamous cell carcinoma (if adenosine Mixed cancer, more than 50% squamous cell carcinoma can be screened; esophagogastric junction squamous cell carcinoma), and has not received systemic anti-tumor therapy before, or for patients who have received neoadjuvant / adjuvant and radical concurrent chemoradiotherapy, the time of the last chemotherapy Screening can be performed if the time to recurrence or progression exceeds 6 months.

[0110] Test drug:

[0111] Drug A: PD-1, prepared according to the method in patent application WO2017054646A;

[0112] Drug B: paclitaxel, Peking Union Medical College Pharmaceutical Factory, 5mL: 30mg;

[0113] Drug C: cisplatin, Jiangsu Hansoh Pharmaceutical Co., Ltd., 6mL: 30mg. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure relates to the use of anti-PD-1 antibodies in combination with paclitaxel and platinum compounds in preparation of medicaments for the treatment of esophageal cancer. Specifically, theinvention provides application of an anti-PD-1 antibody or an antigen binding fragment thereof in combination with a paclitaxel compound and a platinum compound to prepare drugs for treating the esophageal squamous cell carcinoma or esophageal adenosine monophosphate carcinoma. The scheme shows a synergistic effect of drug combination.

Description

technical field [0001] This disclosure relates to the use of an anti-PD-1 antibody in combination with a taxane compound and a platinum compound in the preparation of a drug for treating esophageal cancer. Background technique [0002] Esophageal cancer (Esophageal cancer) refers to a type of malignant tumor that occurs in the epithelium of the esophageal mucosa. The incidence of tumors ranks eighth in the world and the death rate ranks sixth. More than 50% of esophageal cancers occur in China[]. In 2015, there were 477,900 new patients with esophageal cancer in my country; from 2001 to 2011, the incidence rate of male tumors ranked 5th, and the mortality rate ranked 4th, while the incidence rate and mortality rate among females showed a year-by-year decline trend. More than 90% of esophageal cancer types are squamous cell carcinoma, and there are obvious regional differences. The provinces with high incidence of esophageal cancer are Hebei, Henan, Fujian and Chongqing, foll...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61K31/337A61K33/243
CPCA61K31/337A61K33/24A61K39/395A61P35/00A61K2300/00
Inventor 邹建军杨清
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com